This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

II. Significance of Phenomenon to Therapy With Cycloserine

PAUL D. HOEPRICH, MD

Arch Intern Med. 1963;112(3):405-414.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In 1954, cycloserine (Oxamycin, D-4--amino-3-isoxazolidinone) was discovered in three laboratories in the United States to be a fermentation product of three species of Streptomyces.^1-3 A flurry of reports followed, indicating cycloserine was of good effect in the treatment of a wide variety of non-acid-fast^4-14 as well as acid-fast^15-18 microbial infections. However, there has been little recent interest in the application of cycloserine to the treatment of infections caused by non-acid-fast microorganisms in this country—in contrast with interest abroad.^8,9,12-14

Lack of establishment of cycloserine as an antibiotic useful in treating other than mycobacterial infections relates to at least two factors: (1) by conventional in vitro susceptibility testing, non-acid-fast bacteria generally appear to be resistant to cycloserine; (2) as employed in tuberculotherapy, untoward reactions occur rather frequently.

By simultaneous testing of 293 clinical isolates of bacteria representative of 11 bacterial groups, using two synthetic media which differed only . . . [Full Text PDF of this Article]

Author Affiliations
SALT LAKE CITY

Associate Professor of Medicine and Chief, Division of Infectious Diseases, Department of Internal Medicine, University of Utah College of Medicine.; From the Division of Infectious Diseases of the Department of Internal Medicine, University of Utah College of Medicine and the Salt Lake County General Hospital.

Footnotes
Received for publication Jan 25, 1963; accepted March 21.

Supported in part by a grant-in-aid from Eli Lilly and Company and by grants 2E-39 and E-1792 from the National Institute of Allergy and Infectious Diseases, United States Public Health Service, Department of Health, Education, and Welfare, Bethesda 14, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?